Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Rating of "Moderate Buy" by Analysts

Mersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight brokerages that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $6.00.

Several research firms have weighed in on MRSN. Robert W. Baird lowered their price target on shares of Mersana Therapeutics from $4.00 to $3.00 and set a "neutral" rating for the company in a research note on Wednesday, August 14th. Citigroup assumed coverage on shares of Mersana Therapeutics in a research report on Friday, November 15th. They set a "buy" rating and a $5.00 price target on the stock.

Mersana Therapeutics Price Performance

Shares of MRSN stock traded up $0.07 during trading hours on Tuesday, hitting $2.37. 1,051,996 shares of the company were exchanged, compared to its average volume of 1,593,237. The firm has a fifty day simple moving average of $2.08 and a 200 day simple moving average of $1.98. Mersana Therapeutics has a 52-week low of $1.22 and a 52-week high of $6.28. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 13.35.

Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) last posted its quarterly earnings data on Wednesday, November 13th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.08. The firm had revenue of $12.60 million for the quarter, compared to analysts' expectations of $7.53 million. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. The business's quarterly revenue was up 63.6% on a year-over-year basis. During the same quarter last year, the company posted ($0.35) EPS. On average, research analysts expect that Mersana Therapeutics will post -0.61 earnings per share for the current year.

Insider Activity

In related news, CEO Martin H. Jr. Huber sold 50,423 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $1.76, for a total transaction of $88,744.48. Following the transaction, the chief executive officer now owns 116,327 shares in the company, valued at $204,735.52. This represents a 30.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 70,849 shares of company stock worth $129,184 over the last 90 days. 11.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MRSN. US Bancorp DE bought a new stake in shares of Mersana Therapeutics during the 3rd quarter valued at $31,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Mersana Therapeutics in the 3rd quarter worth $34,000. Intech Investment Management LLC purchased a new position in shares of Mersana Therapeutics in the 3rd quarter worth $52,000. Quarry LP bought a new stake in shares of Mersana Therapeutics in the 3rd quarter worth about $57,000. Finally, Algert Global LLC bought a new stake in shares of Mersana Therapeutics in the 2nd quarter worth about $90,000. Institutional investors own 93.92% of the company's stock.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.